Ivabradine in Heart Failure with Reduced Ejection Fraction (HFrEF): A Narrative Review of Clinical Outcomes

https://doi.org/10.22146/jmpf.88590

Rizky Hidayaturahmah(1*), Erin Khoerunisa(2), Nisa Yulianti Suprahman(3), Fia Novitasari(4)

(1) Department of Pharmacy, Faculty of Science, Sumatera Institut of Technology, South Lampung
(2) Department of Pharmacy, Faculty of Science, Sumatera Institut of Technology, South Lampung
(3) Department of Pharmacy, Faculty of Science, Sumatera Institut of Technology, South Lampung
(4) Department of Pharmacy, Faculty of Science, Sumatera Institut of Technology, South Lampung
(*) Corresponding Author

Abstract


Background: Therapy for heart failure with reduced ejection fraction (HFrEF) patients is complex, involving several combinations of treatments, but there are still some problems, such as rehospitalization, reduced ejection fraction values, increased heart rate, and decreased quality of life. Ivabradine, a selective heart rate-lowering agent, offers adjunctive therapeutic benefits.

Objective: This study aims to determine the characteristics of HFrEF patients who received additional therapy with ivabradine and to determine how ivabradine affects their clinical outcomes.

Methods: This narrative review searched articles on PubMed, Cochrane Library, Google Scholar, and ScienceDirect. The research was limited to randomized controlled trial articles, observational studies, and cohorts with international and national English and/or Indonesian articles published in the last 10 years.

Results: Twenty-eight studies (n=36,765) met the problem formulation and inclusion criteria were analyzed. Patients receiving ivabradine were predominantly male (74.9%), aged 56-65 years (81.9%), and had a history of smoking. Most patients had heart rate ≥70 bpm (75.4%), LVEF ≤30% (55.3%), BMI ≥28 kg/m² (87.1%), and NYHA class II-III (85.5%). The addition of ivabradine to the clinical outcome of HFrEF patients reduces heart rate (15.7 bpm), blood pressure (SBP: -4.4 mmHg; DBP: -0.9 mmHg), rehospitalization, and mortality, while improving LVEF and stroke volume, and quality of life. Adverse effects included manageable bradycardia and transient visual disturbances.

Conclusion: Ivabradine effectively improves clinical outcomes in HFrEF patients as adjunct therapy, with significant benefits in cardiac function, symptom control, and prognosis.


Keywords


Characteristics; Clinical Outcome; Effectiveness; HFrEF; Ivabradine

Full Text:

PDF


References

  1. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2
  2. PERKI KKJ dan K. Pedoman Tatalaksana Gagal Jantung. Perhimpun Dr Spes Kardiovask Indonesia. Published online 2015:848-853.
  3. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Hear Fail. 2008;1(2):91-97. doi:10.1161/CIRCHEARTFAILURE.107.743146
  4. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. doi:10.1016/S0140-6736(18)32279-7
  5. Kementerian Kesehatan RI. Riset Kesehatan Dasar (Riskesdas). Published online 2018. httpswwwkemkesgoidarticleview21093000002penyakit-Jantung-Koroner-Didominasi-Masy-KotahtmltextData20Riskesdas20201820juga20melapo
  6. Kementerian Kesehatan RI. Permenkes Nomor 15 Tahun 2018. Published online 2018.
  7. Utami AD, Kartika IR. Terapi Komplementer Terhadap Penurunan Nyeri Pada Pasien Gastritis: a Literatur Review. REAL Nurs J. 2018;1(3):123-132. doi:10.32883/rnj.v1i3.341
  8. Maulani D, Siagian E. Hubungan Pengetahuan Dan Kebersihan Urogenital Dengan Infeksi Saluran Kemih. J Penelit Perawat Prof. 2022;4(4):153-158.
  9. Kementerian Kesehatan Republik RI. Penyakit Jantung Penyebab Kematian Terbanyak ke-2 di Indonesia. Kementerian Kesehatan Republik Indonesia. Published online 2020.
  10. Volterrani M, Iellamo F. Complementary and Synergic Role of Combined Beta-blockers and Ivabradine in Patients with Chronic Heart Failure and Depressed Systolic Function: A New Therapeutic Option? Card Fail Rev. 2016;2(2):130-136. doi:10.15420/cfr.2016:12:1
  11. Lam CSP, Gamble GD, Ling LH, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018;39(20):1770-1780. doi:10.1093/eurheartj/ehy005
  12. Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The Clinical Use of Ivabradine. J Am Coll Cardiol. 2017;70(14):1777-1784. doi:10.1016/j.jacc.2017.08.038
  13. Tse S, Mazzola N. Ivabradine (Corlanor) for heart failure: The first selective and specific if inhibitor. P T. 2015;40(12):810-814. https://pmc.ncbi.nlm.nih.gov/articles/PMC4671466/
  14. Mirembe R, C C. Kerndt DN. Ivabradine. Published online 2022.
  15. Bouabdallaoui N, O’Meara E, Bernier V, et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Hear Fail. 2019;6(6):1199-1207. doi:10.1002/ehf2.12513
  16. Bocchi EA, Böhm M, Borer JS, Ford I. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population. Cardiol Switz. 2015;131(4):218-224. doi:10.1159/000380812
  17. Erdem FH, Ozturk S, Öztürk S, et al. The effects of ivabradine on left ventricular synchronization and tei index in patients with systolic heart failure. Acta Cardiol Sin. 2017;33(1):58-65. doi:10.6515/ACS20160205B
  18. Böhm M, Borer JS, Camm J, et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: Insights from the SHIFT Holter substudy. Eur J Heart Fail. 2015;17(5):518-526. doi:10.1002/ejhf.258
  19. Reil JC, Tardif JC, Ford I, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62(21):1977-1985. doi:10.1016/j.jacc.2013.07.027
  20. Hamill V, Ford I, Fox K, et al. Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. Am J Med. 2015;128(10):1102-1108. doi:10.1016/j.amjmed.2015.04.042
  21. Çavuşoğlu Y, Kozan Ö, Temizhan A, Küçükoğlu MS. Resting heart rate and real-life treatment modalities in outpatients with left ventricular systolic dysfunction study: A multicenter, prospective, observational, and national registry. Anatol J Cardiol. 2021;25(5):304-312. doi:10.14744/AnatolJCardiol.2020.13247
  22. Othman KMS, Mostafa MAR, Yosef AE, Abdeltawab AA. Safety and efficacy of off-label use of ivabradine in patients with acute heart failure. J Saudi Hear Assoc. 2019;31(4):179-187. doi:10.1016/j.jsha.2019.05.006
  23. Zachariah D, Stevens D, Sidorowicz G, Salek MS. Quality of life improvement in older patients with heart failure initiated on ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study. Int J Cardiol. 2017;249:313-318. doi:10.1016/j.ijcard.2017.08.001
  24. Lopatin YM, Cowie MR, Grebennikova AA, Sisakian HS. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program 2018;260:113-117. doi: Internatio. 2018;260:113-117. doi:10.1016/j.ijcard.2017.12.093
  25. Riccioni G, Masciocco L, Benvenuto A, Saracino P. Ivabradine Improves Quality of Life in Subjects with Chronic Heart Failure Compared to Treatment with β-Blockers: Results of a Multicentric Observational APULIA Study. Pharmacology. 2014;92(5-6):276-280. doi:10.1159/000355169
  26. Zugck C, Martinka P, Stöckl G. Ivabradine Treatment in a Chronic Heart Failure Patient Cohort: Symptom Reduction and Improvement in Quality of Life in Clinical Practice. Adv Ther. 2014;31(9):961-974. doi:10.1007/s12325-014-0147-3
  27. Liu YX, Chen W, Lin X, et al. Initiating ivabradine during hospitalization in patients with acute heart failure: A real-world experience in China. Clin Cardiol. 2022;45(9):928-935. doi:10.1002/clc.23880
  28. Tsutsui H, Momomura S, Yamashina A, et al. Heart rate control with if inhibitor, ivabradine, in Japanese patients with chronic heart failure–A randomized, double-blind, placebo-controlled phase II study–. Circ J. 2016;80(3):668-676. doi:10.1253/circj.CJ-15-1112
  29. Rohm I, Kretzschmar D, Pistulli R, et al. Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure. J Immunol Res. 2016;2016:1-12. doi:10.1155/2016/6949320
  30. Tsutsui H, Momomura SI, Yamashina A, et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure ― J-SHIFT study ―. Circ J. 2019;83(10):2049-2060. doi:10.1253/circj.CJ-19-0227
  31. Mullasari A, Mahajan A, Chanana BB, et al. Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study. Cardiol Ther. 2020;9(2):505-521. doi:10.1007/s40119-020-00200-8
  32. Tavazzi L, Swedberg K, Komajda M, et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: Insights from the SHIFT study. Eur J Heart Fail. 2013;15(11):1296-1303. doi:10.1093/eurjhf/hft102
  33. Hidalgo FJ, Anguita M, Castillo JC, Rodríguez S. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study. Int J Cardiol. 2016;217:7-11. doi:10.1016/j.ijcard.2016.04.136
  34. Swedberg K, Komajda M, Böhm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose?: Findings from the SHIFT (Systolic Heart failure treatment with the I f inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59(22):1938-1945. doi:10.1016/j.jacc.2012.01.020
  35. Elder DH, Mohan M, Cochrane L, Charles H, Lang CC. Characterizing Patients with Chronic Heart Failure in Community Care After Hospitalization: A Potential Role for Ivabradine. Cardiovasc Ther. 2015;33(3):104-108. doi:10.1111/1755-5922.12117
  36. Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: A prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60(15):1323-1329. doi:10.1016/j.jacc.2012.06.031
  37. Borer JS, Böhm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: The SHIFT Study. Eur Heart J. 2012;33(22):2813-2820. doi:10.1093/eurheartj/ehs259
  38. Das D, Savarese G, Dahlström U, et al. Ivabradine in heart failure: The representativeness of SHIFT (Systolic Heart Failure Treatment with the IF Inhibitor Ivabradine Trial) in a broad population of patients with chronic heart failure. Circ Hear Fail. 2017;10(9):1-9. doi:10.1161/CIRCHEARTFAILURE.117.004112
  39. Dierckx R, Cleland JGF, Parsons S, et al. Prescribing patterns to optimize heart rate. Analysis of 1,000 consecutive outpatient appointments toasingle heart failure clinic over a 6-month period. JACC Hear Fail. 2015;3(3):224-230. doi:10.1016/j.jchf.2014.11.003
  40. Bagriy AE, Schukina E V, Samoilova O V, Pricolota OA. Addition of Ivabradine to β-Blocker Improves Exercise Capacity in Systolic Heart Failure Patients in a Prospective, Open-Label Study. Adv Ther. 2015;32(2): Adv Ther. 2015;32(2):108-119. doi:10.1007/s12325-015-0185-5.
  41. Elakabawi KH, Aly MM, ElAzam THA, Mahmoud EAE. Effect of Ivabradine on recurrent hospitalization in patients with chronic systolic heart failure. Int J Adv Res. 2015;3(12):1090-1099. doi:10.1093/eurheartj/ehs259
  42. Borer JS, Böhm M, Ford I, Robertson M. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Caridology. 2014;113(3):497-503. doi:10.1016/j.amjcard.2013.10.033
  43. Laksmi IAA, Triana KY, Putra P wira K. The Correlation Between Hypertension and Aritmia With Mortality of Congestive Heart Failure Patients. J Cent Res Publ Midwifery Nurs. 2018;2(2):39-44. https://core.ac.uk/download/pdf/266979535.pdf
  44. Regitz-Zagrosek V. Sex and Gender Differences in Heart Failure. Int J Hear Fail. 2020;2(3):157-181. doi:10.36628/ijhf.2020.0004
  45. Grubb AF, Pumill CA, Greene SJ, Wu A, Chiswell K, Mentz RJ. Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center. Am Heart J. 2020;230:25-34. doi:10.1016/j.ahj
  46. Nicolozakes AW, Binkley PF, Leier C V. Hemodynamic Effects of Smoking in Congestive Heart Failure. Am J Med Sci. 1988; Am J Med Sci. 1988;296(6):377-380. doi:10.1097/00000441-198812000-00002
  47. Rahayu MS. Hubungan Indeks Massa Tubuh Dengan Penyakit Jantung Koroner Di Rumah Sakit Umum Cut Meutia Kabupaten Aceh Utara. AVERROUS J Kedokt dan Kesehat Malikussaleh. 2016;2(1):9-16. doi:10.29103/averrous.v2i1.400
  48. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet London Engl. 2010;376(9744):886-894. doi:10.1016/S0140-6736(10)61259-7
  49. 49. Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the treatment of cardiovascular diseases. Circ J. 2019;83(2):252-260. doi:10.1253/circj.CJ-18-1184
  50. Sari PR, Rampengan SH, Panda AL. Hubungan Kelas Nyha Dengan Fraksi Ejeksi Pada Pasien Gagal Jantung Kronik Di Blu/Rsup Prof. Dr. R.D. Kandou Manado. e-CliniC. 2013;1(2). doi:10.35790/ecl.1.2.2013.3266
  51. Lim FY, Yap J, Gao F, Teo LL, Lam CSP, Yeo KK. Correlation of the New York Heart Association classification and the cardiopulmonary exercise test: A systematic review. Int J Cardiol. Int J Cardiol. 2018;263(2017):88-93. doi:10.1016/j.ijcard.2018.04.021
  52. Tambuwun CFD, Panda AL, Rampengan SH. Gambaran pasien gagal jantung dengan penyakit hipertensi yang menjalani rawat inap di RSUP Prof. Dr. R. D. Kandou Manado periode September – November 2016. e-CliniC. 2016;4(2). doi:10.35790/ecl.4.2.2016.14680
  53. Laksono S. Heart Failure Clinic: A Practical Guide for Health Practitioners in Hospitals. J Kesehat Pasak Bumi Kalimantan. 2023;5(1):32-36. doi:10.30872/j.kes.pasmi.kal.v5i1.7408
  54. Yuniadi Y. Gagal Jantung Kongestif dan Fibrilasi Atrium: Apa Terapi Terbaik? Indones J Cardiol. 2017;37(1):1-5. doi:10.30701/ijc.v37i1.549
  55. Reed M, Kerndt CCND. Ivabradine. In: StatPearls. Treasure Island (FL). StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK507783/
  56. Saputra RI, Adnyana IMO, Laksmidewi AP, Gelgel AM, Widyadharma IPE. Penurunan Fraksi Ejeksi Ventrikel Kiri dalam Enam Bulan Meningkatkan Faktor Resiko Gangguan Kognitif Penderita Gagal Jantung Sistolik. J Kesehat Andalas. 2020;9(1):94-99. doi:10.25077/jka.v9i1.1278
  57. Jefferson AL, Himali JJ, Beiser AS, Au R. Cardiac index is associated with brain aging: The Framingham Heart Study. Natl Inst Heal. 2010;122(7):690-697. doi:10.1161/CIRCULATIONAHA.109.905091.Cardiac
  58. Deedwania P. Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure. Drugs. 2013;73(14):1569-1586. doi:10.1007/s40265-013-0117-0
  59. Group TSR. A Randomized Trial of Intensive versus Standard Blood- Pressure Control. Dep Heal Hum Serv - USA. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939.A
  60. Cowie MR. Ivabradine: The start of a SHIFT in heart failure treatment. Interv Cardiol. 2013;5(1):21-31. doi:10.2217/ica.12.78
  61. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City cardiomyopathy questionnaire: A new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245-1255. doi:10.1016/S0735-1097(00)00531-3
  62. Ekman I, Chassany O, Komajda M, Böhm M. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study. Eur Hear J. 2011;32(19):2395-2404. doi:10.1093/eurheartj/ehr343.
  63. American Heart Association. HIGHLIGHTS of the 2015 American Heart Association Guidelines Update for CPR and ECC. AHA Guidelines Highlights Project Team. http://www.heart.org/. Published online 2015.
  64. Ruzieh M, Sirianni N, Ammari Z, et al. Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience. PACE - Pacing Clin Electrophysiol. 2017;40(11):1242-1245. doi:10.1111/pace.13182



DOI: https://doi.org/10.22146/jmpf.88590

Article Metrics

Abstract views : 536 | views : 313

Refbacks

  • There are currently no refbacks.


Copyright (c) 2026 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats